Development asset linked to Doppel Farmaceutici in public FDA and regional records.
pharma · Persistent Corneal Epithelial Defect (PCED) · Recent onset Type 1 Diabetes
Doppel Farmaceutici
Dompe' Farmaceutici S.p.A.
Doppel Farmaceutici drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Via Martiri delle Foibe 1, Cortemaggiore (PC), Emilia-Romagna 29016, IT, napoli HQ
1994 Founded
393 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Via Martiri delle Foibe 1, Cortemaggiore (PC), Emilia-Romagna 29016, IT, napoli
- Founded
- 1994
- Employees
- 393
- Programs
- 11
- Drugs
- 14
- Patents
- 0
Doppel Farmaceutici pipeline
Portfolio lens on 14 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Doppel Farmaceutici drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Doppel Farmaceutici in public FDA and regional records.
-
cenegermin
Sensory organs (S01)Sensory organs (S01) compound in Doppel Farmaceutici's portfolio. Molecular target: Neurotrophic tyrosine kinase receptor.
- Target
- Neurotrophic tyrosine kinase receptor
- Mechanism
- Neurotrophic tyrosine kinase receptor agonist
-
Development asset linked to Doppel Farmaceutici in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Doppel Farmaceutici in public FDA and regional records.
-
Development asset linked to Doppel Farmaceutici in public FDA and regional records.
-
Development asset linked to Doppel Farmaceutici in public FDA and regional records.
-
Development asset linked to Doppel Farmaceutici in public FDA and regional records.
-
Development asset linked to Doppel Farmaceutici in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Doppel Farmaceutici in public FDA and regional records.
-
Development asset linked to Doppel Farmaceutici in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M3.
- Target
- Muscarinic acetylcholine receptor M3
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist